Non-Invasive Cardiometry and Ultrasound Guided Inferior Vena Cava Collapsibility Index in Assessing Fluid Responsiveness
Key facts
- Who runs it
- National Cancer Institute, Egypt
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 43 people enrolled
- Started
- 6 Sept 2021
- Ended
- 1 Dec 2023
- Type of study
- Interventional
- Treatments tested
- OSYPKA Medical ICONTM Noninvasive CardiometerTM Model C3
- Fujifilm Sonosite M-Turbo C Ultrasound system
- Record updated
- 17 January 2024
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- ASA class I and II
- 18yrs ≥ Age ≤ 60yrs
- Fulfilling criteria of sepsis, as per The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Who cannot take part
- Anticipated surgery or dialysis in the next 8hrs
- Active bleeding
- Cardiac tamponade
- Congestive heart failure
- New York Heart Association (NYHA) III and IV cardiac patients
- Severe ARDS (acute respiratory distress syndrome)
- End-stage kidney disease (ESKD) patients with a creatinine clearance (CrCl) <50ml/min
- Age < 18yrs or > 60yrs
- Lack of consent
- Aortic regurge
- Arrythmias
- Chest wall oedema
- Child B and Child C hepatic patients
- Massive bilateral pleural effusion
- Mechanical ventilation
- More than 4hrs after meeting criteria of septic shock
- Tense ascites
- Vasopressor infusion (before or after inclusion in the study)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
43 patients between 18-60 years presenting with criteria of sepsis (life-threatening organ dysfunction caused by a dysregulated host response to infection, suspected or documented infection and an acute increase ≥2 SOFA [Sequential Organ Failure Assessment] points) will be enrolled in our study. Approval of the ethical committee and informed written consent from first degree relatives will be issued. They will be given a full and detailed explanation of the intended study protocol and will be informed about the potential benefits of the development of a successful technique as well as the potential side-effects.
Read full original descriptionShow less
To compare the efficacy of non-invasive cardiometry and ultrasound (US) guided inferior vena cava (IVC) collapsibility when assessing the response of septic patients to fluid therapy guidelines of The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3); in the first six hours of ICU admission .
The group in the trial
- Non-invasive cardiometryOther group
OSYPKA Medical ICONTM Noninvasive CardiometerTM Model C3 A technique for the non-invasive determination of SV, CO, cardiac index, stroke index and HR along with other hemodynamic parameters such as preload (Thoracic Fluid Index), afterload and others. The changes of impedance over time are integrated in a complex algorithm that allows to measure CO and the other above-mentioned parameters.
Treatment: OSYPKA Medical ICONTM Noninvasive CardiometerTM Model C3 and Fujifilm Sonosite M-Turbo C Ultrasound system
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Non-Invasive Cardiometry and Ultrasound Guided Inferior Vena Cava Collapsibility Index in Assessing Fluid Responsiveness in Septic Cancer Patients
- Record updated
- 17 January 2024